Current Status of Gene Engineering Cell Therapeutics

Ex vivo manipulations of autologous patient’s cells or gene-engineered cell therapeutics have allowed the development of cell and gene therapy approaches to treat otherwise incurable diseases. These modalities of personalized medicine have already shown great promises including product commercialization for some rare diseases. The transfer of a chimeric antigen receptor or T cell receptor genes into autologous T cells has led to very promising outcomes for some cancers, and particularly for hematological malignancies. In addition, gene-engineered cell therapeutics are also being explored to induce tolerance and regulate inflammation. Here, we review the latest gene-engineered cell therapeutic approaches being currently explored to induce an efficient immune response against cancer cells or viruses by engineering T cells, natural killer cells, gamma delta T cells, or cytokine-induced killer cells and to modulate inflammation using regulatory T cells.

• Publication year

  2018

• Venue

  Frontiers in Immunology

• Publication date

  2018-02-05

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.3389/fimmu.2018.00153PMID 29459866PMCID 5807372
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children

  2017cited by this paper
• Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC‐Specific Chimeric Antigen Receptor

  2017cited by this paper
• A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy

  2017cited by this paper
• A versatile system for rapid multiplex genome-edited CAR T cell generation

  2017cited by this paper
• Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts

  2017cited by this paper
• Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.

  2017cited by this paper
• Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy

  2017cited by this paper
• Title : NY-ESO-1 TCR single edited central memory and memory stem T cells to treat multiple myeloma without inducing GvHD

  2017influential reference
• Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

  2017cited by this paper
• 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.

  2017cited by this paper
• Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

  2017cited by this paper
• Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

  2017cited by this paper
• Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

  2017cited by this paper
• Phase I study of cord blood‐derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma

  2017cited by this paper
• HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells

  2017cited by this paper
• Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants

  2017cited by this paper
• The Principles of Engineering Immune Cells to Treat Cancer.

  2017cited by this paper
• Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection

  2017cited by this paper
• Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm

  2017cited by this paper
• FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.

  2017cited by this paper
• NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease.

  2017cited by this paper
• Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.

  2016cited by this paper
• Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043)

  2016cited by this paper
• T cells for viral infections after allogeneic hematopoietic stem cell transplant.

  2016cited by this paper
• Driving gene-engineered T cell immunotherapy of cancer

  2016cited by this paper
• Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.

  2016cited by this paper
• CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

  2016cited by this paper
• Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease

  2016cited by this paper
• Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application

  2016cited by this paper
• Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

  2016cited by this paper
• Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.

  2016cited by this paper
• Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

  2016cited by this paper
• Toxicities of chimeric antigen receptor T cells: recognition and management.

  2016cited by this paper
• Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections

  2016cited by this paper
• Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea

  2016cited by this paper
• Type 1 diabetes immunotherapy using polyclonal regulatory T cells

  2015cited by this paper
• Cytokine-induced killer (CIK) cells: from basic research to clinical translation

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

  2015influential reference
• Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.

  2015influential reference
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies

  2015cited by this paper
• Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

  2015cited by this paper
• Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients

  2015cited by this paper
• CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

  2015cited by this paper
• T cell engineering as therapy for cancer and HIV: our synthetic future

  2015cited by this paper
• The pharmacology of second-generation chimeric antigen receptors

  2015cited by this paper
• Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer

  2015cited by this paper
• Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

  2014cited by this paper
• A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

  2014cited by this paper
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014cited by this paper
• Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.

  2014cited by this paper
• Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up.

  2014cited by this paper
• Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice

  2014cited by this paper
• Engineered T cells for cancer therapy

  2014cited by this paper
• Are natural killer cells superior CAR drivers?

  2014cited by this paper
• Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT

  2014cited by this paper
• Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

  2013influential reference
• Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.

  2013cited by this paper
• Mesenchymal stromal cells in transplantation rejection and tolerance.

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• The basic principles of chimeric antigen receptor design.

  2013cited by this paper
• Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells

  2013cited by this paper
• Treatment of patients with advanced cancer with the natural killer cell line NK-92.

  2013cited by this paper
• Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.

  2013cited by this paper
• Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

  2013cited by this paper
• Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

  2013cited by this paper
• Targeting of acute myeloid leukaemia by cytokine‐induced killer cells redirected with a novel CD123‐specific chimeric antigen receptor

  2013cited by this paper
• Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

  2013cited by this paper
• Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

  2013cited by this paper
• Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers

  2013cited by this paper
• Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

  2013influential reference
• Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

  2013cited by this paper
• HLA engineering of human pluripotent stem cells.

  2013cited by this paper
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

  2013cited by this paper
• How to treat cancer

  2013cited by this paper
• Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

  2012cited by this paper
• Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease.

  2012cited by this paper
• Improved Activation toward Primary Colorectal Cancer Cells by Antigen-Specific Targeting Autologous Cytokine-Induced Killer Cells

  2012cited by this paper
• Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT

  2012cited by this paper
• Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

  2012cited by this paper
• Molecular Mechanisms of Treg-Mediated T Cell Suppression

  2012cited by this paper
• Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

  2012cited by this paper
• Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study

  2012cited by this paper
• T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis.

  2011cited by this paper
• Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.

  2011cited by this paper
• Third‐party virus‐specific T cells eradicate adenoviraemia but trigger bystander graft‐versus‐host disease

  2011cited by this paper
• T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

  2011cited by this paper
• Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.

  2011cited by this paper
• Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression

  2011cited by this paper
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

  2011cited by this paper
• Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction

  2011cited by this paper
• A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

  2011cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• Adoptive transfer of DNT cells induces long-term cardiac allograft survival and augments recipient CD4(+)Foxp3(+) Treg cell accumulation.

  2011cited by this paper

• Immune reconstruction after allogeneic hematopoietic stem cell transplantation: rules, mechanisms, and applications.

  2026cites this paper
• Advances in cancer immunotherapy: The role of super NK and super CAR-T cells.

  2025cites this paper
• Click Chemistry‐Mediated Polymannose Surface‐Engineering of Natural Killer Cells for Immunotherapy of Triple‐Negative Breast Cancer

  2024cites this paper
• Phenotyping of CAR T cells.

  2022cites this paper
• Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells

  2021cites this paper
• Imaging of T-cell Responses in the Context of Cancer Immunotherapy

  2021cites this paper
• Immunophenotypic Analysis of CAR-T Cells.

  2020cites this paper
• Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time

  2020cites this paper
• The clinical potential of gene editing as a tool to engineer cell-based therapeutics

  2020cites this paper
• Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells.

  2020influential citation
• How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies

  2020cites this paper
• Implications of genome plasticity for drug development

  2020cites this paper
• Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer

  2020cites this paper
• Harnessing the perinuclear actin cap (pnAC) to influence nanocarrier trafficking and gene transfection efficiency in skeletal myoblasts using nanopillars.

  2020cites this paper
• Cellular immunotherapies for cancer

  2020cites this paper
• Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models

  2020cites this paper
• The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology

  2020cites this paper
• Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery

  2020cites this paper
• The potential markers of NK-92 associated to cytotoxicity against K562 cells.

  2020cites this paper
• Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells

  2019cites this paper
• Engineering antigen‐specific NK cell lines against the melanoma‐associated antigen tyrosinase via TCR gene transfer

  2019cites this paper
• Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives

  2019cites this paper
• T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human

  2019cites this paper
• Imaging of T-cells and their responses during anti-cancer immunotherapy

  2019cites this paper
• Future prospects for CD8+ regulatory T cells in immune tolerance

  2019cites this paper
• Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells.

  2019cites this paper
• Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes

  2018cites this paper
• Chimeric Antigen Receptor T-Cell Therapy.

  2018cites this paper
• Cousins at work: How combining medical with optical imaging enhances in vivo cell tracking

  2018cites this paper
• Emerging stem cell based strategies for treatment of childhood diseases.

  2018cites this paper
• Current Status of the Clinical Development of Gene Therapy

  2018cites this paper
• Étude comparative de la réglementation des médicaments de thérapie innovante entre différents pays et de son impact dans leur développement clinique et leur commercialisation

  2018cites this paper
• Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance

  2018cites this paper
• Cellular therapies: Day by day, all the way.

  2018cites this paper
• Current Status of Biological Nursing Science Education for Clinical Nurses in General Hospital

  2017cites this paper